It has been estimated that maternal drug abuse and its treatment is placing epidemic-proportions of offspring at considerable risk each year in the United States alone. Exposure of pregnant humans and laboratory animals to opiates can result in a range of problems for their fetuses including developmental retardation. Since the etiology of many of the developmental abnormalities is unknown, it is important that we understand the types and functions of opioid systems in normal developing mammalian brain. Use of this knowledge to elucidate the mechanism by which opiate drugs influence opioid receptor mediated actions during early brain development may allow us to determine, prevent or reverse pathological effects of these drugs. The objectives of this proposal are to continue the characterization of opioid receptors in rodent brain focusing on the 55 kDa molecular weight mu and the kappa opioid binding sites that we have detected in the perinatal period. By affinity labeling with [125I]-beta-endorphin the glycoprotein nature and subcellular compartmentation of the 55 kDa mu site will be examined to determined whether it is an incompletely processed precursor or a transiently expressed functional receptor. Using homologous and heterologous competition binding assays followed by a computer analysis, the subtype specificity of mouse perinatal mu and kappa sites will be probed. The sequence of appearance of opioid receptor subtypes will be correlated with that of the endogenous opioid peptides, G protein subunits and the neurotrophic functions described below that are prevalent at this stage of development. The role of individual receptor subtypes and their mechanism of action in opioid receptor mediated inhibition of brain DNA synthesis and ornithine decarboxylase activity will be investigated in cultured rat fetal brain cell aggregates and in vivo. Mixed agonist-antagonists such as buprenorphine will be administered to pregnant rats or cultured rat fetal brain cell aggregates and the consequences to normal expression of opioid receptors and of their neurotrophic effects assessed. Since buprenorphine has recently been demonstrated to be a good candidate for pharmacotherapy in cocaine and /or heroin abuse, these results may be of significance to the treatment of maternal drug abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA005412-06
Application #
2117623
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Program Officer
Riddle, Robert D
Project Start
1987-09-30
Project End
1995-06-30
Budget Start
1992-09-01
Budget End
1995-06-30
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Saint Louis University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Ikeda, Hiroko; Miyatake, Mayumi; Koshikawa, Noriaki et al. (2010) Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation. J Biol Chem 285:38415-27
Hahn, Jason W; Jagwani, Shana; Kim, Eunhae et al. (2010) Mu and kappa opioids modulate mouse embryonic stem cell-derived neural progenitor differentiation via MAP kinases. J Neurochem 112:1431-41
Miyatake, Mayumi; Rubinstein, Tal J; McLennan, Gregory P et al. (2009) Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways. J Neurochem 110:662-74
McLennan, Gregory P; Kiss, Alexi; Miyatake, Mayumi et al. (2008) Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J Neurochem 107:1753-65
Kim, Eunhae; Clark, Amy L; Kiss, Alexi et al. (2006) Mu- and kappa-opioids induce the differentiation of embryonic stem cells to neural progenitors. J Biol Chem 281:33749-60
Belcheva, Mariana M; Clark, Amy L; Haas, Paul D et al. (2005) Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J Biol Chem 280:27662-9
Belcheva, Mariana M; Tan, Yun; Heaton, Virginia M et al. (2003) Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling. Mol Pharmacol 64:1391-401
Belcheva, Mariana M; Haas, Paul D; Tan, Yun et al. (2002) The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells. J Pharmacol Exp Ther 303:909-18
Fabian, G; Bozo, B; Szikszay, M et al. (2002) Chronic morphine-induced changes in mu-opioid receptors and G proteins of different subcellular loci in rat brain. J Pharmacol Exp Ther 302:774-80
Belcheva, Mariana M; Coscia, Carmine J (2002) Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. Neurosignals 11:34-44

Showing the most recent 10 out of 27 publications